Because of the increased knowledge about the underlying cytokine network in psoriasis, selective systemic agents for the treatment of moderate-to-severe psoriasis have been developed during the past decade. The marked upregulation of JAK/STAT pathways in psoriasis and the identification of multiple key mediators in psoriasis pathogenesis that signal through JAK/STAT pathways led to investigation of JAK proteins as potential therapeutic targets for psoriasis treatment. A novel JAK-STAT inhibitor, tofacitinib, has been tested in preclinical studies for the treatment of psoriasis. Considering the satisfactory safety profile and the encouraging efficacy observed in the Phase II and Phase III trials, tofacitinib may represent an important therapeutic to be included into the psoriasis paradigm.

Chiricozzi, A., Faleri, S., Saraceno, R., Bianchi, L., Buonomo, O.c., Chimenti, S., et al. (2015). Tofacitinib for the treatment of moderate-to-severe psoriasis. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 11(4), 443-455 [10.1586/1744666X.2015.1013534].

Tofacitinib for the treatment of moderate-to-severe psoriasis

CHIRICOZZI, ANDREA;SARACENO, ROSITA;BIANCHI, LUCA;BUONOMO, ORESTE CLAUDIO;CHIMENTI, SERGIO;CHIMENTI, MARIA SOLE
2015-01-01

Abstract

Because of the increased knowledge about the underlying cytokine network in psoriasis, selective systemic agents for the treatment of moderate-to-severe psoriasis have been developed during the past decade. The marked upregulation of JAK/STAT pathways in psoriasis and the identification of multiple key mediators in psoriasis pathogenesis that signal through JAK/STAT pathways led to investigation of JAK proteins as potential therapeutic targets for psoriasis treatment. A novel JAK-STAT inhibitor, tofacitinib, has been tested in preclinical studies for the treatment of psoriasis. Considering the satisfactory safety profile and the encouraging efficacy observed in the Phase II and Phase III trials, tofacitinib may represent an important therapeutic to be included into the psoriasis paradigm.
2015
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
IL-23; Th17; psoriasis; small molecules; tofacitinib
Chiricozzi, A., Faleri, S., Saraceno, R., Bianchi, L., Buonomo, O.c., Chimenti, S., et al. (2015). Tofacitinib for the treatment of moderate-to-severe psoriasis. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 11(4), 443-455 [10.1586/1744666X.2015.1013534].
Chiricozzi, A; Faleri, S; Saraceno, R; Bianchi, L; Buonomo, Oc; Chimenti, S; Chimenti, Ms
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Tofacitinib for the treatment.pdf

solo utenti autorizzati

Descrizione: Articolo principale
Licenza: Copyright dell'editore
Dimensione 376.43 kB
Formato Adobe PDF
376.43 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/119586
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 33
social impact